Table 1.
Participant characteristics, presented as mean ± SD or count (percentage)
| Characteristics | MET | SU |
|---|---|---|
| Number of participants | 282 | 89 |
| Age at onset, y | 59 ± 9 | 55 ± 9 |
| Age at initiation, y | 59 ± 9 | 58 ± 9 |
| Male gender | 167 (59) | 56 (62) |
| Diabetes duration | 110 ± 101 | |
| 0–3 mo | 142 (50) | ‐ |
| >3 mo | 140 (50) | ‐ |
| Baseline HbA1c, mmol/mol | 58.9 ± 14.9 | 58.7 ± 13.3 |
| HbA1c at 6 mo, mmol/mol | 49.2 ± 6.2 | 49.6 ± 6.7 |
| HbA1c control status, n (%) | ||
| <53 mmol/mol | 85 (37) | ‐ |
| ≥53 mmol/mol | 142 (63) | ‐ |
| SU status, n (%) | ||
| SU‐only | ‐ | 37 (42) |
| SU‐combi | ‐ | 52 (58) |
| Baseline BMI, kg/m2 | 30.6 ± 5.1 | 29.5 ± 5.4 |
| Baseline blood pressure, mmHg | ||
| Systolic | 140.6 ± 18.5 | 140.5 ± 18.9 |
| Diastolic | 83.0 ± 11.8 | 83.4 ± 11.4 |
| Baseline lipid levels, mmol/L | ||
| HDL cholesterol | 1.2 ± 0.3 | 1.2 ± 0.4 |
| Total cholesterol | 5.1 ± 1.1 | 4.7 ± 1.2 |
| Triglycerides | 2.1 ± 1.1 | 2.2 ± 1.3 |
| GRSs | ||
| β‐cell secretion‐related (β‐GRS) | ‐ | 15.2 ± 2.4 |
| Insulin sensitivity‐related (IS‐GRS) | 6.0 ± 1.4 | ‐ |
| Total | 71.1 ± 5.6 | 70.0 ± 5.1 |
| MET dose at 6 mo, n (%) | ||
| ≤500 mg | 117 (41) | ‐ |
| 750‐1000 mg | 95 (34) | ‐ |
| >1000 mg | 70 (25) | ‐ |
| SU group, n (%) | ||
| Glibenclamide | ‐ | 1 (1) |
| Tolbutamide | ‐ | 27 (30) |
| Gliclazide | ‐ | 53 (60) |
| Glimepiride | ‐ | 8 (9) |
| SU dose at 6 mo (DDDs), n (%) | ||
| ≤0.5 | ‐ | 50 (56) |
| >0.5 | ‐ | 39 (44) |
Abbreviations: DDD, defined daily dose; MET, metformin; SU, sulphonylurea derivatives.